Literature DB >> 20854180

Targeting Fas in osteoresorptive disorders.

Natasa Kovacic1, Danka Grcevic, Vedran Katavic, Ivan Kresimir Lukic, Ana Marusic.   

Abstract

IMPORTANCE OF THE FIELD: Fas receptor is a mediator of the external apoptotic pathway in many cells and tissues. It is proposed that Fas receptor mediates osteoresorptive effects of estrogen deficiency and local/systemic inflammation. AREAS COVERED IN THIS REVIEW: This review covers the past two decades of research on the expression and function of the Fas-Fas ligand system on bone cells, involvement in the pathogenesis of osteoresorption and potential therapeutic modulation. WHAT THE READER WILL GAIN: We review the structure, biological function and intracellular signaling pathways of the Fas-Fas ligand system emphasizing the role of the non-apoptotic signaling pathways in bone cells, particularly osteoblast differentiation. We also present data on the in vitro expression and function of the Fas-Fas ligand system on osteoblast/osteoclast lineage cells, animal and human studies confirming its involvement in osteoresorptive disorders and potential therapeutic approaches to modulate its function. TAKE HOME MESSAGE: Tissue specific therapeutic approaches need to be established to modify the Fas-Fas ligand system in osteoresorptive disorders as systemic targeting has many side effects. The most promising approach would be to target Fas signaling molecules coupled with osteoblast/osteoclast differentiation pathways, but a precise definition of these targets is still needed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20854180      PMCID: PMC3035871          DOI: 10.1517/14728222.2010.522347

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  111 in total

1.  Apoptosis a relevant therapeutic target in rheumatoid arthritis?

Authors:  M D Smith; J G Walker
Journal:  Rheumatology (Oxford)       Date:  2003-12-16       Impact factor: 7.580

2.  CD4+ T cells regulate CD8+ T cell-mediated cutaneous immune responses by restricting effector T cell development through a Fas ligand-dependent mechanism.

Authors:  Anton V Gorbachev; Robert L Fairchild
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

Review 3.  Sex hormones as negative regulators of lymphopoiesis.

Authors:  P W Kincade; K L Medina; G Smithson
Journal:  Immunol Rev       Date:  1994-02       Impact factor: 12.988

4.  CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells.

Authors:  Bryan C Barnhart; Patrick Legembre; Eric Pietras; Concetta Bubici; Guido Franzoso; Marcus E Peter
Journal:  EMBO J       Date:  2004-07-22       Impact factor: 11.598

5.  Modulation of survival in osteoblasts from postmenopausal women.

Authors:  C García-Moreno; M P Catalán; A Ortiz; L Alvarez; C De la Piedra
Journal:  Bone       Date:  2004-07       Impact factor: 4.398

6.  Vitamin D inhibits Fas ligand-induced apoptosis in human osteoblasts by regulating components of both the mitochondrial and Fas-related pathways.

Authors:  Gustavo Duque; Khadija El Abdaimi; Janet E Henderson; Abderrahim Lomri; Richard Kremer
Journal:  Bone       Date:  2004-07       Impact factor: 4.398

7.  Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele.

Authors:  Saoussen Karray; Chantal Kress; Sylvain Cuvellier; Catherine Hue-Beauvais; Diane Damotte; Charles Babinet; Matthieu Lévi-Strauss
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

8.  The APO-1/Fas (CD95) receptor is expressed in homozygous MRL/lpr mice.

Authors:  S M Mariani; B Matiba; E A Armandola; P H Krammer
Journal:  Eur J Immunol       Date:  1994-12       Impact factor: 5.532

Review 9.  Modulation of death receptor pathways in oncology.

Authors:  E G E de Vries; T Timmer; N H Mulder; C M M van Geelen; W T A van der Graaf; D C J Spierings; M N de Hooge; J A Gietema; S de Jong
Journal:  Drugs Today (Barc)       Date:  2003       Impact factor: 2.245

10.  A proinflammatory role for Fas in joints of mice with collagen-induced arthritis.

Authors:  Hoang Tu-Rapp; André Hammermüller; Eilhard Mix; Hans-Jürgen Kreutzer; Roland Goerlich; Hansjürgen Köhler; Horst Nizze; Hans-Jürgen Thiesen; Saleh M Ibrahim
Journal:  Arthritis Res Ther       Date:  2004-07-19       Impact factor: 5.156

View more
  6 in total

1.  A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling.

Authors:  Daniel R Jones
Journal:  Ann Transl Med       Date:  2015-08

2.  Impact of FasL Stimulation on Sclerostin Expression and Osteogenic Profile in IDG-SW3 Osteocytes.

Authors:  Adela Kratochvilova; Alice Ramesova; Barbora Vesela; Eva Svandova; Herve Lesot; Reinhard Gruber; Eva Matalova
Journal:  Biology (Basel)       Date:  2021-08-07

3.  Identification of Potentially Pathogenic Variants Associated with Recurrence in Medication-Related Osteonecrosis of the Jaw (MRONJ) Patients Using Whole-Exome Sequencing.

Authors:  Songmi Kim; Seyoung Mun; Wonseok Shin; Kyudong Han; Moon-Young Kim
Journal:  J Clin Med       Date:  2022-04-12       Impact factor: 4.964

4.  Osteoblastogenesis from synovial fluid-derived cells is related to the type and severity of juvenile idiopathic arthritis.

Authors:  Elvira Lazić; Marija Jelušić; Danka Grčević; Ana Marušić; Nataša Kovačić
Journal:  Arthritis Res Ther       Date:  2012-06-12       Impact factor: 5.156

5.  FasL (rs763110) gene polymorphism is not associated with susceptibility to rheumatoid arthritis in Croatian population.

Authors:  Marinko Artuković; Marina Ikić Matijašević; Antonio Markotić; Alan Šućur; Danka Grčević; Nataša Kovačić; Darja Flegar; Asja Stipić Marković; Dino Šisl; Irena Artuković; Tomislav Kelava
Journal:  Croat Med J       Date:  2020-12-31       Impact factor: 1.351

6.  FasL Modulates Expression of Mmp2 in Osteoblasts.

Authors:  Eva Svandova; Barbora Vesela; Hervé Lesot; Jeremy Sadoine; Anne Poliard; Eva Matalova
Journal:  Front Physiol       Date:  2018-09-19       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.